Nemdx Inc.’s collaboration with leading research centers has yielded remarkable insights into ALS biomarkers. By utilizing their proprietary assays, researchers were able to identify potential biomarker candidates associated with both sporadic and familial ALS. These findings are paving the way for more targeted therapies and improved ALS patient care.